Browsing Barts Cancer Institute by Subject "biomarkers"
Now showing items 1-6 of 6
-
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.
(2022-11)OBJECTIVES: To test the feasibility of a randomised controlled trial (RCT) of aspirin and/or vitamin D3 in active surveillance (AS) low/favourable intermediate risk prostate cancer (PCa) patients with Prolaris® testing. ... -
Genetic and immune landscape evolution in MMR-deficient colorectal cancer.
(2023-11-15)Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phenotype may also promote ... -
Liquid biopsy in lymphoma: Is it primed for clinical translation?
(2021-08)The simultaneous growth in our understanding of lymphoma biology and the burgeoning therapeutic options has come with a renewed drive for precision-based approaches and how best to incorporate them into contemporary and ... -
Non-Invasive Biomarkers for Early Lung Cancer Detection
(MDPI, 2022-11-24)Worldwide, lung cancer (LC) is the most common cause of cancer death, and any delay in the detection of new and relapsed disease serves as a major factor for a significant proportion of LC morbidity and mortality. Though ...